- Home
- PLRX vs ORIC Comparison
PLRX vs ORIC Comparison
Compare PLRX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- ORIC
- Stock Information
- Founded
- PLRX 2015
- ORIC 2014
- Country
- PLRX United States
- ORIC United States
- Employees
- PLRX N/A
- ORIC N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- ORIC Health Care
- Exchange
- PLRX Nasdaq
- ORIC Nasdaq
- Market Cap
- PLRX 84.7M
- ORIC 362.9M
- IPO Year
- PLRX 2020
- ORIC 2020
- Fundamental
- Price
- PLRX $1.16
- ORIC $10.31
- Analyst Decision
- PLRX Hold
- ORIC Strong Buy
- Analyst Count
- PLRX 10
- ORIC 8
- Target Price
- PLRX $9.79
- ORIC $18.83
- AVG Volume (30 Days)
- PLRX 1.4M
- ORIC 1.3M
- Earning Date
- PLRX 08-06-2025
- ORIC 08-11-2025
- Dividend Yield
- PLRX N/A
- ORIC N/A
- EPS Growth
- PLRX N/A
- ORIC N/A
- EPS
- PLRX N/A
- ORIC N/A
- Revenue
- PLRX N/A
- ORIC N/A
- Revenue This Year
- PLRX N/A
- ORIC N/A
- Revenue Next Year
- PLRX N/A
- ORIC N/A
- P/E Ratio
- PLRX N/A
- ORIC N/A
- Revenue Growth
- PLRX N/A
- ORIC N/A
- 52 Week Low
- PLRX $1.10
- ORIC $3.90
- 52 Week High
- PLRX $16.10
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- PLRX 34.14
- ORIC 71.78
- Support Level
- PLRX $1.23
- ORIC $8.85
- Resistance Level
- PLRX $1.43
- ORIC $10.99
- Average True Range (ATR)
- PLRX 0.11
- ORIC 0.69
- MACD
- PLRX -0.02
- ORIC 0.01
- Stochastic Oscillator
- PLRX 3.92
- ORIC 77.10
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.